| Literature DB >> 35488244 |
Yuji Shishido1, Tomoyuki Matsunaga2, Masahiro Makinoya2, Wataru Miyauchi2, Shota Shimizu2, Kozo Miyatani2, Chihiro Uejima2, Masaki Morimoto2, Yuki Murakami2, Takehiko Hanaki2, Kyoichi Kihara2, Manabu Yamamoto2, Naruo Tokuyasu2, Shuichi Takano2, Teruhisa Sakamoto2, Hiroaki Saito3, Toshimichi Hasegawa2, Yoshiyuki Fujiwara2.
Abstract
BACKGROUND: Thoracoscopic esophagectomy has been extensively used worldwide as a curative surgery for patients with esophageal cancer; however, complications such as anastomotic leakage and stenosis remain a major concern. Therefore, the objective of this study was to evaluate the efficacy of circular stapling anastomosis with indocyanine green (ICG) fluorescence imaging, which was standardized for cervical esophagogastric anastomosis after thoracoscopic esophagectomy.Entities:
Keywords: Anastomotic leakage; Anastomotic stenosis; Cervical esophagogastric anastomosis; Circular stapling anastomosis; Esophageal cancer; Indocyanine green fluorescence imaging; Propensity score matching; Thoracoscopic esophagectomy
Mesh:
Substances:
Year: 2022 PMID: 35488244 PMCID: PMC9052471 DOI: 10.1186/s12893-022-01602-2
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.030
Fig. 1Patient selection for the evaluation of cervical esophagogastric anastomosis after thoracoscopic esophagectomy
Fig. 2Procedures in indocyanine green (ICG) circular anastomosis. a The right gastroepiploic artery was contrasted with ICG; b The site where the wall of the gastric tube had a uniform contrast with ICG; c End-to-side esophagogastric anastomosis was performed on the posterior wall of the gastric tube using a 25-mm DST Series EEA circular stapler; d The stump of the gastric tube was sectioned and closed using the Signia stapling system with a 60 mm purple cartridge
Characteristics of patients
| Before matching | After matching | |||||
|---|---|---|---|---|---|---|
| Classical group | ICG circular group | Classical group | ICG circular group | |||
| (n = 82) | (n = 39) | (n = 33) | (n = 33) | |||
| Age (years) | 0.892 | 0.872 | ||||
| Median (quartiles) | 66 (61–72) | 66 (61–71) | 65 (61–73) | 67 (63–73) | ||
| Sex | 0.914 | 0.282 | ||||
| Male | 70 (85%) | 33 (85%) | 30 (90%) | 27 (82%) | ||
| Female | 12 (15%) | 6 (15%) | 3 (9%) | 6 (18%) | ||
| Body mass index (kg/m2) | 21.2 ± 3.1 | 22.2 ± 3.3 | 0.083 | 21.8 ± 3.1 | 21.9 ± 3.3 | 0.677 |
| Serum albumin level (g/dL) | 4.2 ± 0.4 | 4.1 ± 0.4 | 0.494 | 4.1 ± 0.4 | 4.1 ± 0.4 | 0.985 |
| Brinkman index | 0.733 | 0.278 | ||||
| Median (quartiles) | 800 (445–1000) | 860 (435–1000) | 820 (600–1140) | 840 (405–1000) | ||
| ECOG performance status | 0.586 | 0.601 | ||||
| 0 | 68 (83%) | 34 (87%) | 27 (82%) | 28 (85%) | ||
| 1 | 12 (15%) | 5 (13%) | 5 (15%) | 5 (15%) | ||
| 2 | 2 (2%) | 0 (0%) | 1 (3%) | 0 (0%) | ||
| Comorbidity | ||||||
| Diabetes | 15 (18%) | 4 (10%) | 0.256 | 10 (30%) | 4 (12%) | 0.071 |
| Cardiovascular disease | 10 (12%) | 6 (15%) | 0.628 | 2 (6%) | 5 (15%) | 0.230 |
| Obstructive ventilation failure | 27 (33%) | 13 (33%) | 0.965 | 10 (30%) | 11 (33%) | 0.792 |
| ASA-PS score | 0.021 | 0.115 | ||||
| 1 | 11 (13%) | 1 (3%) | 3 (9%) | 1 (3%) | ||
| 2 | 63 (77%) | 28 (72%) | 27 (82%) | 23 (70%) | ||
| 3 | 8 (10%) | 10 (26%) | 3 (9%) | 9 (27%) | ||
| Histological type | 0.009 | 1.000 | ||||
| Squamous cell carcinoma | 78 (95%) | 30 (77%) | 30 (91%) | 30 (91%) | ||
| Adenocarcinoma | 2 (2%) | 6 (15%) | 2 (6%) | 2 (6%) | ||
| Others | 2 (2%) | 3 (8%) | 1 (3%) | 1 (3%) | ||
| Tumor location | 0.229 | 0.642 | ||||
| Upper thoracic | 11 (13%) | 6 (15%) | 5 (15%) | 6 (18%) | ||
| Middle thoracic | 43 (52%) | 16 (41%) | 15 (46%) | 16 (49%) | ||
| Lower thoracic | 24 (29%) | 11 (28%) | 11 (33%) | 7 (21%) | ||
| Abdominal | 4 (5%) | 6 (15%) | 2 (6%) | 4 (12%) | ||
| cT | 0.405 | 0.667 | ||||
| 1 | 36 (44%) | 16 (41%) | 16 (49%) | 14 (42%) | ||
| 2 | 14 (17%) | 11 (28%) | 5 (15%) | 9 (27%) | ||
| 3 | 31 (38%) | 11 (28%) | 11 (33%) | 9 (27%) | ||
| 4a | 1 (1%) | 1 (3%) | 1 (3%) | 1 (3%) | ||
| cN | 0.224 | 0.420 | ||||
| 0 | 44 (54%) | 28 (72%) | 19 (58%) | 24 (73%) | ||
| 1 | 17 (21%) | 5 (13%) | 7 (21%) | 4 (12%) | ||
| 2 | 20 (24%) | 5 (13%) | 7 (21%) | 5 (15%) | ||
| 3 | 1 (1%) | 1 (3%) | 0 (0%) | 0 (0%) | ||
| cStage | 0.296 | 0.393 | ||||
| 1 | 32 (39%) | 14 (36%) | 16 (49%) | 13 (39%) | ||
| 2 | 19 (23%) | 14 (36%) | 5 (15%) | 10 (30%) | ||
| 3 | 31 (38%) | 11 (28%) | 12 (36%) | 10 (30%) | ||
| Neoadjuvant chemotherapy | 0.974 | 1.000 | ||||
| Absent | 36 (44%) | 17 (44%) | 16 (49%) | 16 (49%) | ||
| Present | 46 (56%) | 22 (56%) | 17 (52%) | 17 (52%) | ||
ECOG Eastern Cooperative Oncology Group, ASA-PS American Society of Anesthesiologists physical status
Fig. 3Changes in anastomotic methods for cervical esophagogastric anastomosis after thoracoscopic esophagectomy. Changes in the classical and ICG circular groups, and the annual incidence rates of anastomotic leakage and stenosis in anastomotic methods for cervical esophagogastric anastomosis after thoracoscopic esophagectomy are shown
Perioperative outcomes of patients with esophageal cancer after thoracoscopic esophagectomy
| Before matching | After matching | |||||
|---|---|---|---|---|---|---|
| Classical group | ICG circular group | Classical group | ICG circular group | |||
| (n = 82) | (n = 39) | (n = 33) | (n = 33) | |||
| Abdominal approach | < 0.001 | < 0.001 | ||||
| Open | 34 (42%) | 0 (0%) | 15 (46%) | 0 (0%) | ||
| Laparoscopic | 48 (59%) | 39 (100%) | 18 (55%) | 33 (100%) | ||
| Lymph node dissection | 0.180 | 1.000 | ||||
| Two-field | 18 (22%) | 13 (33%) | 10 (30%) | 10 (30%) | ||
| Three-field | 64 (78%) | 26 (67%) | 23 (70%) | 23 (70%) | ||
| Route of reconstruction | 0.070 | 0.131 | ||||
| Retrosternal | 68 (83%) | 37 (95%) | 27 (82%) | 31 (94%) | ||
| Posterior mediastinal | 14 (17%) | 2 (5%) | 6 (18%) | 2 (6%) | ||
| Shape of the gastric tube | 0.001 | 0.003 | ||||
| Wide | 21 (26%) | 0 (0%) | 8 (24%) | 0 (0%) | ||
| Narrow | 61 (74%) | 39 (100%) | 25 (76%) | 33 (100%) | ||
| Total operative time (min) | 634 ± 89 | 617 ± 53 | 0.573 | 638 ± 100 | 616 ± 51 | 0.753 |
| Volume of blood loss (mL) | 186 ± 219 | 103 ± 97 | 0.038 | 251 ± 298 | 93 ± 89 | 0.009 |
| Postoperative complications | ||||||
| Anastomotic leakage | 28 (34%) | 3 (8%) | 0.002 | 13 (39%) | 3 (9%) | 0.004 |
| Anastomotic stenosis | 29 (35%) | 8 (21%) | 0.097 | 15 (46%) | 7 (21%) | 0.037 |
| Pneumonia | 18 (22%) | 11 (28%) | 0.451 | 8 (24%) | 9 (27%) | 0.778 |
| Recurrent nerve paralysis | 14 (17%) | 2 (5%) | 0.070 | 7 (21%) | 2 (6%) | 0.073 |
| Postoperative hospital stay | 29 (22–44) | 20 (16–28) | < 0.001 | 30 (25–44) | 20 (17–28) | < 0.001 |
Multivariate logistic regression analyses of anastomotic leakage
| OR | 95% CI | ||
|---|---|---|---|
| Brinkman index (≥ 800) | 3.538 | 0.842–14.860 | 0.084 |
| Anastomotic method (classical group) | 5.983 | 1.469–24.359 | 0.013 |
OR odds ratio, CI confidence interval
Univariate logistic regression analyses of anastomotic leakage
| Anastomotic leakage | |||||
|---|---|---|---|---|---|
| Absent (n = 50) | Present (n = 16) | OR | 95% CI | ||
| Age (years) | |||||
| <65 | 20 (40%) | 8 (50%) | 1.500 | 0.484–4.651 | 0.483 |
| ≥65 | 30 (60%) | 8 (50%) | 1 | ||
| Sex | |||||
| Male | 42 (84%) | 15 (94%) | 2.857 | 0.329–24.795 | 0.341 |
| Female | 8 (16%) | 1 (6%) | 1 | ||
| Body mass index (kg/m2) | |||||
| <22 | 24 (48%) | 10 (63%) | 1.806 | 0.569–5.726 | 0.316 |
| ≥ 22 | 26 (52%) | 6 (38%) | 1 | ||
| Serum albumin level (g/dL) | |||||
| <4 | 20 (40%) | 5 (31%) | 0.682 | 0.206–2.261 | 0.531 |
| ≥ 4 | 30 (60%) | 11 (69%) | 1 | ||
| Brinkman index | |||||
| <800 | 24 (48%) | 3 (19%) | 0.250 | 0.063–0.986 | 0.048 |
| ≥ 800 | 26 (52%) | 13 (81%) | 1 | ||
| Performance status | |||||
| 0 | 42 (84%) | 13 (81%) | 0.825 | 0.191–3.574 | 0.797 |
| 1, 2 | 8 (16%) | 3 (19%) | 1 | ||
| Diabetes | |||||
| Absent | 39 (78%) | 13 (81%) | 1.222 | 0.295–5.069 | 0.782 |
| Present | 11 (22%) | 3 (19%) | 1 | ||
| Cardiovascular disease | |||||
| Absent | 46 (92%) | 13 (81%) | 0.377 | 0.075–1.901 | 0.237 |
| Present | 4 (8%) | 3 (19%) | |||
| Obstructive ventilation failure | |||||
| Absent | 36 (72%) | 9 (56%) | 0.500 | 0.156–1.603 | 0.243 |
| Present | 14 (28%) | 7 (44%) | 1 | ||
| ASA-PS score | |||||
| 1 | 3 (6%) | 1 (6%) | 1.044 | 0.101–10.806 | 0.971 |
| 2, 3 | 47 (94%) | 15 (94%) | 1 | ||
| Histological type | |||||
| Squamous cell carcinoma | 45 (90%) | 15 (94%) | 1.667 | 0.180–15.425 | 0.653 |
| Others | 5 (10%) | 1 (6%) | 1 | ||
| Tumor location | |||||
| Ut, Mt | 31 (62%) | 11 (69%) | 1.348 | 0.406–4.484 | 0.626 |
| Lt, Ae | 19 (38%) | 5 (31%) | 1 | ||
| cT | |||||
| 1 | 21 (42%) | 9 (56%) | 1.776 | 0.570–5.531 | 0.322 |
| 2, 3, 4a | 29 (58%) | 7 (44%) | 1 | ||
| cN | |||||
| Absent | 33 (66%) | 10 (63%) | 0.859 | 0.267–2.764 | 0.798 |
| Present | 17 (34%) | 6 (38%) | 1 | ||
| cStage | |||||
| 1 | 20 (40%) | 9 (56%) | 1.929 | 0.618–6.020 | 0.258 |
| 2, 3 | 30 (60%) | 7 (44%) | 1 | ||
| Neoadjuvant chemotherapy | |||||
| Absent | 22 (44%) | 10 (63%) | 2.121 | 0.668–6.739 | 0.202 |
| Present | 28 (56%) | 6 (38%) | 1 | ||
| Abdominal approach | |||||
| Open | 11 (22%) | 4 (25%) | 1.182 | 0.317–4.400 | 0.803 |
| Laparoscopic | 39 (78%) | 12 (75%) | 1 | ||
| Lymph node dissection | |||||
| Two-field | 15 (30%) | 5 (31%) | 1.061 | 0.314–3.585 | 0.925 |
| Three-field | 35 (70%) | 11 (69%) | 1 | ||
| Route of reconstruction | |||||
| Retrosternal | 43 (86%) | 15 (94%) | 2.442 | 0.277–21.519 | 0.421 |
| Posterior mediastinal | 7 (14%) | 1 (6%) | 1 | ||
| Shape of gastric tube | |||||
| Wide | 5 (10%) | 3 (19%) | 2.077 | 0.437–9.871 | 0.358 |
| Narrow | 45 (90%) | 13 (81%) | 1 | ||
| Total operative time (min) | |||||
| <600 | 20 (40%) | 6 (38%) | 0.900 | 0.282–2.870 | 0.859 |
| ≥ 600 | 30 (60%) | 10 (63%) | 1 | ||
| Blood loss (mL) | |||||
| <100 | 26 (52%) | 7 (44%) | 0.718 | 0.231–2.229 | 0.566 |
| ≥ 100 | 24 (48%) | 9 (56%) | 1 | ||
| Anastomotic method | |||||
| ICG circular group | 30 (60%) | 3 (19%) | 0.154 | 0.039–0.610 | 0.008 |
| Classical group | 20 (40%) | 13 (81%) | 1 | ||
OR odds ratio, CI confidence interval, ASA-PS American Society of Anesthesiologists physical status